241 related articles for article (PubMed ID: 1976046)
1. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
4. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
Evans WE; Relling MV
Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
[TBL] [Abstract][Full Text] [Related]
5. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
6. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
7. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
8. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
9. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
10. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
12. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
13. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
14. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Dolzan V; Rudolf Z; Breskvar K
Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
[TBL] [Abstract][Full Text] [Related]
15. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
[TBL] [Abstract][Full Text] [Related]
16. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
[TBL] [Abstract][Full Text] [Related]
18. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
[TBL] [Abstract][Full Text] [Related]
20. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
